Nurse Practitioner, Adult Health · West Bend, WI
NPI
1497862908
Since 2006
Specialty
Nurse Practitioner, Adult Health
Code 363LA2200X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1700 W Paradise Dr
West Bend, WI, 53095
Phone (262) 334-3451
Groups this clinician bills Medicare through
Medicare paid, 2024
$11K
230 services
Medicare patients, 2024
92
Average age 65
Drug cost, 2024
$1.5M
2,483 prescriptions
Company payments, 2025
$284
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Karen 'Kate' M Glasenapp was code 99214 (office e&m - established), 173 times for 89 patients. In total Karen 'Kate' M Glasenapp billed 230 services in 7 codes, and Medicare paid $11K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-12-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 173 | 89 | $56.81 | $9,829 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 26 | 21 | $10.47 | $272 |
| 95251 Test - Miscellaneous | Facility | 15 | 11 | $20.58 | $309 |
By year: 2022 $16K for 263 services; 2023 $12K for 197 services; 2024 $11K for 230 services.
Medicare prescription drug claims, 2024
In 2024, the drug Karen 'Kate' M Glasenapp prescribed most often to Medicare patients was Ozempic (Semaglutide), with 305 prescriptions and refills. In total Karen 'Kate' M Glasenapp wrote 2,483 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 305 | 445 | 56 | $423K |
| Mounjaro Tirzepatide | 215 | 240 | 30 | $251K |
| Trulicity Dulaglutide | 163 | 208 | 29 | $204K |
| Metformin Hcl Er Metformin Hcl | 158 | 333 | 40 | $1,589 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 122 | 336 | 46 | $16K |
| Humulin 70/30 Kwikpen Insulin Nph Hum/Reg Insulin Hm | 99 | 180 | 28 | $37K |
| Jardiance Empagliflozin | 86 | 202 | 19 | $118K |
| Topiramate Generic | 85 | 228 | 29 | $949 |
| Glimepiride Generic | 80 | 196 | 25 | $524 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 71 | 192 | 41 | $11K |
| Humalog Kwikpen U-100 Insulin Lispro | 62 | 126 | 22 | $23K |
| Insulin Lispro Kwikpen U-100 Insulin Lispro | 58 | 107 | 20 | $17K |
| Metformin Hcl Generic | 47 | 108 | 11 | $184 |
| Tresiba Flextouch U-200 Insulin Degludec | 44 | 73 | Under 11 | $43K |
| Tresiba Flextouch U-100 Insulin Degludec | 44 | 135 | 16 | $29K |
Brand drugs: 1,601 claims; generic drugs: 551 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Karen 'Kate' M Glasenapp $284 ($284 in general payments such as food, travel and fees) from 1 company. The largest payer was Novo Nordisk Inc with $284.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 4 | $284 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.